GRI Bio (GRI) Competitors $5.54 -0.33 (-5.62%) As of 11:21 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GRI vs. BCTX, CARM, COCP, SLGL, MEIP, IMNN, SYBX, LPTX, NRSN, and IXHLShould you be buying GRI Bio stock or one of its competitors? The main competitors of GRI Bio include BriaCell Therapeutics (BCTX), Carisma Therapeutics (CARM), Cocrystal Pharma (COCP), Sol-Gel Technologies (SLGL), MEI Pharma (MEIP), Imunon (IMNN), Synlogic (SYBX), Leap Therapeutics (LPTX), NeuroSense Therapeutics (NRSN), and Incannex Healthcare (IXHL). These companies are all part of the "pharmaceutical products" industry. GRI Bio vs. BriaCell Therapeutics Carisma Therapeutics Cocrystal Pharma Sol-Gel Technologies MEI Pharma Imunon Synlogic Leap Therapeutics NeuroSense Therapeutics Incannex Healthcare BriaCell Therapeutics (NASDAQ:BCTX) and GRI Bio (NASDAQ:GRI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations, community ranking and media sentiment. Do institutionals & insiders have more ownership in BCTX or GRI? 15.4% of BriaCell Therapeutics shares are owned by institutional investors. Comparatively, 34.0% of GRI Bio shares are owned by institutional investors. 5.7% of BriaCell Therapeutics shares are owned by company insiders. Comparatively, 0.1% of GRI Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is BCTX or GRI more profitable? BriaCell Therapeutics' return on equity of 0.00% beat GRI Bio's return on equity.Company Net Margins Return on Equity Return on Assets BriaCell TherapeuticsN/A N/A -191.19% GRI Bio N/A -289.05%-165.01% Does the MarketBeat Community believe in BCTX or GRI? BriaCell Therapeutics received 9 more outperform votes than GRI Bio when rated by MarketBeat users. CompanyUnderperformOutperformBriaCell TherapeuticsOutperform Votes12100.00% Underperform VotesNo VotesGRI BioOutperform Votes3100.00% Underperform VotesNo Votes Do analysts recommend BCTX or GRI? BriaCell Therapeutics currently has a consensus target price of $32.00, suggesting a potential upside of 727.94%. GRI Bio has a consensus target price of $195.50, suggesting a potential upside of 3,428.88%. Given GRI Bio's higher probable upside, analysts plainly believe GRI Bio is more favorable than BriaCell Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BriaCell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00GRI Bio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation & earnings, BCTX or GRI? BriaCell Therapeutics is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBriaCell TherapeuticsN/AN/A-$4.79M-$5.03-0.77GRI BioN/AN/A-$13.04M-$11.56-0.48 Which has more volatility & risk, BCTX or GRI? BriaCell Therapeutics has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500. Comparatively, GRI Bio has a beta of -2.1, suggesting that its share price is 310% less volatile than the S&P 500. Does the media refer more to BCTX or GRI? In the previous week, GRI Bio had 1 more articles in the media than BriaCell Therapeutics. MarketBeat recorded 3 mentions for GRI Bio and 2 mentions for BriaCell Therapeutics. BriaCell Therapeutics' average media sentiment score of 0.94 beat GRI Bio's score of 0.86 indicating that BriaCell Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BriaCell Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GRI Bio 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryBriaCell Therapeutics beats GRI Bio on 8 of the 13 factors compared between the two stocks. Remove Ads Get GRI Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for GRI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRI vs. The Competition Export to ExcelMetricGRI BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.91M$6.94B$5.64B$7.88BDividend YieldN/A2.73%4.57%4.01%P/E Ratio-0.487.1323.1218.71Price / SalesN/A225.38385.6791.56Price / CashN/A65.6738.1634.64Price / Book1.066.416.884.24Net Income-$13.04M$141.90M$3.20B$247.06M7 Day Performance-33.01%-4.37%-2.58%-1.76%1 Month Performance-30.05%-6.78%1.93%-5.32%1 Year Performance-96.70%-8.47%9.78%-0.51% GRI Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRIGRI Bio2.752 of 5 stars$5.54-5.6%$195.50+3,428.9%-96.6%$2.91MN/A-0.481Short Interest ↓Gap UpBCTXBriaCell Therapeutics1.9445 of 5 stars$4.46-0.2%$32.00+617.5%-89.9%$16.54MN/A-0.338CARMCarisma Therapeutics3.3359 of 5 stars$0.39-4.8%$4.94+1,154.8%-84.0%$16.44M$20.27M-0.2520COCPCocrystal Pharma3.2369 of 5 stars$1.58+1.3%$7.00+343.0%-4.7%$16.08MN/A-0.8510Short Interest ↓Gap DownSLGLSol-Gel Technologies2.4421 of 5 stars$0.57+9.7%$5.00+776.6%-48.1%$15.89M$11.71M-1.6850Upcoming EarningsShort Interest ↑Gap UpMEIPMEI Pharma4.3337 of 5 stars$2.35+2.2%$7.00+197.9%-40.8%$15.66M$65.30M-0.41100Short Interest ↓IMNNImunon2.2712 of 5 stars$1.07+12.1%$20.50+1,824.9%-18.6%$15.57M$500,000.00-0.5630Analyst ForecastSYBXSynlogic1.8428 of 5 stars$1.29-0.7%N/A-28.1%$15.10M$8,000.00-0.3180Positive NewsLPTXLeap Therapeutics2.494 of 5 stars$0.39-2.7%$4.92+1,160.7%-86.9%$14.94MN/A-0.2040Earnings ReportUpcoming EarningsAnalyst ForecastShort Interest ↓News CoverageGap DownNRSNNeuroSense Therapeutics0.7563 of 5 stars$1.08+0.9%N/A-39.9%$14.76MN/A-1.6910Gap UpIXHLIncannex Healthcare0.901 of 5 stars$0.80-3.5%N/A-77.8%$14.29M$98,000.00-0.583Positive News Remove Ads Related Companies and Tools Related Companies BCTX Alternatives CARM Alternatives COCP Alternatives SLGL Alternatives MEIP Alternatives IMNN Alternatives SYBX Alternatives LPTX Alternatives NRSN Alternatives IXHL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRI) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GRI Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GRI Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GRI Stock Free GRI Stock Alerts